济南尿酸不高为什么会有痛风石济南痛风怎么天天痛,济南治疗痛风佳的方法,济南尿酸达到多少会得痛风,济南通风有什么症状,山东关节痛风结晶如何治疗,山东出现了痛风石怎么办,济南痛风石症状及治疗办法

SAN FRANCISCO, Nov. 1 (Xinhua) -- Apple announced on Tuesday that its latest iPhone 4S smartphone will be available in China's Hong Kong, South Korea and 13 additional countries next Friday.Customers will be able to pre-order iPhone 4S beginning this Friday, the Cupertino, California-based company said in a statement.The other 13 countries are Albania, Armenia, Bulgaria, El Salvador, Greece, Guatemala, Malta, Montenegro, New Zealand, Panama, Poland, Portugal and Romania.So far, some owners have been complaining about the shorter battery life on their new iPhone 4S handsets. Apple is reportedly investigating the issue and has not made official comments yet.The iPhone 4S looks the same as the previous iPhone 4 but has major hardware upgrade inside. Apple announced sales of more than four million units of iPhone 4S in the three days after its launch in the United States on Oct. 14.The iPhone 4S now is available in 29 countries and is expected to arrive in stores in more than 70 countries by the end of this year.

BEIJING, Dec. 14 (Xinhua) -- China's new yuan-denominated lending in November rose 7.8 billion yuan (1.2 billion U.S. dollars) year-on-year to 562.2 billion yuan, the People's Bank of China, the central bank (PBOC), announced Wednesday.New loans in the month were smaller compared to that in October, which stood at 586.8 billion yuan.By the end of November, the outstanding broad money supply (M2), which covers cash in circulation and all deposits, rose 12.7 percent year-on-year to 82.55 trillion yuan, according to data released by the PBOC.Meanwhile, the narrow measure of money supply (M1), which covers cash in circulation plus demand deposits, increased 7.8 percent year-on-year to 28.14 trillion yuan by the end of last month, the figures showed.New yuan deposits last month fell sharply to 324.7 billion yuan, down 262.6 billion yuan year-on-year. Outstanding yuan-denominated deposits totaled 79.51 trillion yuan as of the end of last month, up 13.1 percent year-on-year, however, the growth rate was 6.5 percentage points lower compared to the same period last year.Meanwhile, outstanding foreign currencies-denominated deposits stood at 266.8 billion U.S. dollars, up 12.9 percent year-on-year. New deposits of foreign currencies rose 4.1 billion U.S. dollars year-on-year.

BEIJING, Oct. 11 (Xinhuanet) -- Debates in the medical field developed on Monday as a U.S. government panel recommended that men of all ages should stop getting prostate cancer blood screenings.The United States Preventive Services examined all the evidence and found little if any reduction in deaths from routine P.S.A. screening and suggested that the test does more harm than good to healthy men.The P.S.A. test for prostate cancer, a blood test to screen for a protein that may indicate cancer, has become widely used because it can help detect tiny tumors at a very early sta ge, when they are theoretically most treatable.Unfortunately, according to the task force, the vast majority of the results are false-positives: the men don’t actually have cancer. And most of those found to have cancerous cells would not suffer ill effects because their cancer is so slow-growing that it would not cut short their lives. Those with faster-growing cancers may also not be helped if the cancer is extremely aggressive.After the recommendation came out last week, many prostate cancer specialists have been pushing back.Urologist Dr. Mark DeGuenther said this recommendation is more about saving money than saving lives. He said death rates from prostate cancer have dropped 40 percent since men began getting screened at age 40 and he says it will save taxpayers and patients more money in the long run to diagnose and treat cancers earlier rather than wait and have to provide expensive care for advanced stage cancers."We all agree that we've got to do a better job of figuring out who would benefit from P.S.A. screening," said Dr. Scott Eggener, a prostate cancer specialist at the University of Chicago. "But a blanket statement of just doing away with it altogether ... seems over-aggressive and irresponsible."Dr. Deepak Kapoor, chairman and chief executive of Integrated Medical Professionals, which includes the nation's largest urology practice, said "We will not allow patients to die, which is what will happen if this recommendation is accepted."That task force's recommendation isn't final - it's a draft open for public debate. And obviously the debate is already under way.

WASHINGTON, Jan. 19 (Xinhua) -- New research published this week in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.The study, led by investigators with the Ohio State University Comprehensive Cancer Center, shows that overexpression of two genes called MET and EGFR causes the deregulation of six microRNAs, and that this deregulation leads to gefitinib resistance.The findings support the development of agents that restore the levels of these microRNAs. It offers a new strategy for treating non-small cell lung cancer, which is responsible for about 85 percent of the 221,000 lung-cancer cases and 157,000 deaths that occur annually in the United States. It also suggests that measuring the expression levels of certain microRNAs -- those controlled by the MET gene -- might predict which lung-cancer cases are likely to be resistant to gefitinib.Epidermal growth factor receptor (EGFR) is frequently overexpressed in non-small cell lung cancer, and this leads to uncontrolled cell proliferation. Gefitinib selectively inhibits EGFR activation and triggers cancer cells to self-destruct by apoptosis. However, non-small cell lung cancer cells inevitably develop resistance to the drug. The study reveals how this resistance occurs."Our findings suggest that gefitinib resistance that is caused by MET overexpression is at least partly due to miRNA deregulation, " says principal investigator Carlo Croce.

WASHINGTON, Dec. 7 (Xinhua) -- Drugs that affect the levels of an important brain protein involved in learning and memory reverse cellular changes in the brain seen during aging, according to an animal study published Wednesday in the Journal of Neuroscience. The findings could one day aid in the development of new drugs that enhance cognitive function in older adults.Aging-related memory loss is associated with the gradual deterioration of the structure and function of synapses (the connections between brain cells) in brain regions critical to learning and memory, such as the hippocampus.Recent studies suggested that histone acetylation, a chemical process that controls whether genes are turned on, affects this process. Specifically, it affects brain cells' ability to alter the strength and structure of their connections for information storage, a process known as synaptic plasticity, which is a cellular signature of memory.In the current study, Cui-Wei Xie, of the University of California, Los Angeles, and colleagues found that compared with younger rats, hippocampi from older rats have less brain-derived neurotrophic factor (BDNF) -- a protein that promotes synaptic plasticity -- and less histone acetylation of the Bdnf gene. By treating the hippocampal tissue from older animals with a drug that increased histone acetylation, they were able to restore BDNF production and synaptic plasticity to levels found in younger animals."These findings shed light on why synapses become less efficient and more vulnerable to impairment during aging," said Xie, who led the study. "Such knowledge could help develop new drugs for cognitive aging and aging-related neurodegenerative diseases, such as Alzheimer's disease," she added.